Pfizer and BioNTech antibodies were safe and produced a robust immune response in children aged five to 11. Additionally, they would seek regulatory approval soon.
In participants five to 11 years of age, the antibody was safe, well tolerated and showed vigorous neutralising antibody responses.
The companies plan to submit their data to regulatory bodies in the European Union, the US and around the world quickly.
Kids between the 5-11 age group received a two-dose routine of 10 microgrammes in the trial, against 30 microgrammes for older age groups. Children were trialed at a gap of 21 days.
Under-5s before year-end
The side effects were the same in comparison to those observed in participants 16 to 25 years of age.
Most common side effects have been pain and swelling at the injection site as well as headache, chills and fever.
Israel has authorised vaccinating children aged 5-11 using the Pfizer jab at the lower dosage.
Pfizer and BioNTech are also trialling their medicines on infants and on children aged two to five.
Commonly, Pfizer jab is based on novel mRNA technology that delivers genetic instructions to cells to build the coronavirus spike protein. Concerning, evoke antibodies when bodies encounter the real virus.
Stay tuned with Artifex.News for further updates. Stay Connected, Stay Informed!
Image Credit: Wikimedia Commons
